Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.32 – $0.44
84% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $176.7M | $169.3M | $195.3M | $191.7M | $208.9M | $234.2M | $204.3M | $192.4M |
| Cost of revenue | $107.4M | $109.3M | $103.0M | $88.3M | $82.9M | $98.4M | $92.0M | $109.7M |
| Gross profit | $69.3M | $60.0M | $92.3M | $103.4M | $126.0M | $135.8M | $112.4M | $82.7M |
| Gross margin | 39.2% | 35.4% | 47.3% | 53.9% | 60.3% | 58.0% | 55.0% | 43.0% |
| R&D | $3.1M | $1.7M | $1.3M | $0 | $0 | $2.9M | $7.2M | $2.8M |
| Operating income | $6.3M | −$11.5M | $690.0K | $12.2M | $20.1M | $23.9M | −$7.3M | −$29.0M |
| EBITDA | $12.5M | −$18.0M | $6.8M | $17.9M | $25.8M | $21.3M | −$59.9M | −$22.1M |
| Net income | $8.2M | −$27.7M | −$9.7M | $9.5M | $12.8M | $11.1M | −$77.4M | −$104.8M |
| Net margin | 4.6% | -16.4% | -5.0% | 4.9% | 6.1% | 4.7% | -37.9% | -54.4% |
| EPS (diluted) | 0.17 | -0.56 | -0.19 | 0.14 | 0.18 | 0.16 | -1.10 | -1.49 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $212M | $0.08 | $0.08–$0.08 | 1 |
| 2027 | $222M | $0.08 | $0.08–$0.08 | 1 |
| 2028 | $230M | $0.09 | $0.09–$0.09 | 1 |
Forward consensus · source: Financial Modeling Prep
COMVITA NEW ZEALAND LTD
No one on the platform currently holds CVNZF.
No tracked institution reports a position in CVNZF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2024-04-03 | $0.0139 | 2024-04-24 |
| 2024-04-03 | $0.0018 | 2024-04-24 |
| 2023-10-04 | $0.0417 | 2023-10-26 |
| 2023-10-04 | $0.0053 | 2023-10-26 |
No one on the platform has traded CVNZF yet.
| +0.00% |
| $7M |
| — |
| LNLHFLeanLife Health Inc. | $0.01 | +0.00% | $3M | — |
| NBBTFNatural Beauty Bio-Technology Limited | $0.06 | +0.00% | $122M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.4× historical median P/S.
Fair value ≈ $2.77 · price $0.42 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.